Year All202620252024202320222021202020192018201720162015201420132012201120102007 02.01.18 Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca - Collaboration will evaluate combination of SNDX-6352 with durvalumab (ImfinziTM) in solid tumors - Read More 01.10.18 Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer -Phase Ib/II trial will assess the efficacy, safety, and pharmacokinetics of immunotherapy combination in HR+, HER2- metastatic breast cancer- Read More 11.11.17 Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting - ENCORE 601 data continue to support increased immune responsiveness in both PD-(L)1 refractory and PD-(L)1 naïve NSCLC patients treated with entinostat and KEYTRUDA® (pembrolizumab)-- Biomarker data from PD-1 refractory melanoma cohort shows conversion of a non-inflamed to inflamed tumor microenvironment following treatment with entinostat and KEYTRUDA - Read More 11.07.17 Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update - Pipeline Expanded with Addition of Potential Best-in-Class Menin-MLL-r inhibitors - - Enrollment in First Stage of Colorectal and Second Stage of PD-(L)1 Refractory NSCLC Cohorts of ENCORE 601 Complete - - Company to Host Conference Call Today at 4:30 p.m. ET - Read More 11.07.17 Syndax to Present at the SITC 32nd Annual Scientific Meeting WALTHAM, Mass. , Nov. 7, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced five presentations at the upcoming Society for Read More 10.31.17 Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017 WALTHAM, Mass. , Oct. 31, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, announced today that it will release its third quarter 2017 Read More 10.17.17 Syndax Announces $25 Million Registered Direct Offering of Common Stock WALTHAM, Mass. , Oct. 17, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has agreed to sell 2,021,018 shares Read More 10.17.17 Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors - Compounds Provide Novel Therapeutic Approach for the Potential Treatment of Defined Genetic Subtype of Pediatric and Adult Acute Leukemias - Read More 10.05.17 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin - Enrollment of First Patient Triggers $5 Million Milestone Payment to Syndax - Read More 09.20.17 Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference WALTHAM, Mass. , Sept. 20, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced an update to the time of the Company's presentation at the Cantor Fitzgerald Read More 08.30.17 Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Aug. 30, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Briggs W. Morrison , M.D., Chief Executive Officer of Syndax, will Read More 08.10.17 Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update - PD-1 Refractory Melanoma Cohort of ENCORE 601 Completes Enrollment - - First Patient Dosed in ENCORE 601 Colorectal Cancer Cohort - - Company to Host Conference Call Today at 4:30 p.m. ET - Read More
02.01.18 Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca - Collaboration will evaluate combination of SNDX-6352 with durvalumab (ImfinziTM) in solid tumors - Read More
01.10.18 Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer -Phase Ib/II trial will assess the efficacy, safety, and pharmacokinetics of immunotherapy combination in HR+, HER2- metastatic breast cancer- Read More
11.11.17 Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting - ENCORE 601 data continue to support increased immune responsiveness in both PD-(L)1 refractory and PD-(L)1 naïve NSCLC patients treated with entinostat and KEYTRUDA® (pembrolizumab)-- Biomarker data from PD-1 refractory melanoma cohort shows conversion of a non-inflamed to inflamed tumor microenvironment following treatment with entinostat and KEYTRUDA - Read More
11.07.17 Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update - Pipeline Expanded with Addition of Potential Best-in-Class Menin-MLL-r inhibitors - - Enrollment in First Stage of Colorectal and Second Stage of PD-(L)1 Refractory NSCLC Cohorts of ENCORE 601 Complete - - Company to Host Conference Call Today at 4:30 p.m. ET - Read More
11.07.17 Syndax to Present at the SITC 32nd Annual Scientific Meeting WALTHAM, Mass. , Nov. 7, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced five presentations at the upcoming Society for Read More
10.31.17 Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017 WALTHAM, Mass. , Oct. 31, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, announced today that it will release its third quarter 2017 Read More
10.17.17 Syndax Announces $25 Million Registered Direct Offering of Common Stock WALTHAM, Mass. , Oct. 17, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has agreed to sell 2,021,018 shares Read More
10.17.17 Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors - Compounds Provide Novel Therapeutic Approach for the Potential Treatment of Defined Genetic Subtype of Pediatric and Adult Acute Leukemias - Read More
10.05.17 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin - Enrollment of First Patient Triggers $5 Million Milestone Payment to Syndax - Read More
09.20.17 Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference WALTHAM, Mass. , Sept. 20, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced an update to the time of the Company's presentation at the Cantor Fitzgerald Read More
08.30.17 Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Aug. 30, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Briggs W. Morrison , M.D., Chief Executive Officer of Syndax, will Read More
08.10.17 Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update - PD-1 Refractory Melanoma Cohort of ENCORE 601 Completes Enrollment - - First Patient Dosed in ENCORE 601 Colorectal Cancer Cohort - - Company to Host Conference Call Today at 4:30 p.m. ET - Read More